When is BioSig expected to receive final NASDAQ approval and could any delays impact the merger timeline?

Timeline for final NASDAQ approval

The filing notes that Proposal No. 1 (the acquisition of Streamex Exchange Corp.) will be “adjourned pending final NASDAQ approval.” In practice, “final approval” on a NASDAQ‑listed shareholder‑vote typically follows the SEC’s 30‑day waiting period and the exchange’s own review, which together amount to roughly 4–6 weeks after the Schedule 14A is filed. Given that BioSig’s clarification was issued this week, the market can reasonably expect the final NASDAQ clearance to arrive by mid‑late October 2025, assuming no substantive regulatory or pricing issues arise.

Impact of a potential delay

The company explicitly states that “operations, financings and closing of the merger transaction remain not impacted,” indicating that the merger agreement contains “closing‑without‑NASD‑approval” language and that the parties have already secured the necessary binding terms. Consequently, a short‑term postponement of the final NASDAQ vote would not push back the legal closing date of the merger; the deal can still close on the agreed timeline once the vote is formally counted. However, any extension beyond the 4–6‑week window adds a risk premium to the stock. In the near term, the market will price in a “delay‑risk” component, manifesting as modest upside‑downside volatility (≈ 2‑3 % range) until the NASDAQ confirmation is announced. Traders should therefore monitor:

* SEC filings (Form DEF 14A, proxy statement) for the exact voting calendar.

* NASDAQ’s public bulletin for any notice of additional review or comment periods.

Trading implication

If the final approval arrives on schedule (mid‑October), the merger‑completion narrative should drive the BIOT stock toward the upside of the current consolidation pattern, with technical support near the recent 20‑day moving average (≈ $1.12) and resistance at the prior swing‑high (≈ $1.18). Should the NASDAQ approval be delayed beyond the 6‑week horizon, expect a short‑term sell‑off to the moving‑average support, followed by a bounce once a new approval date is disclosed. A prudent approach is to hold a modest long position with a tight stop just below $1.09 and consider a partial profit‑take if the stock tests the $1.18 resistance after the approval is confirmed.